Results 121 to 130 of about 523,896 (324)
Promoter Prediction on a Genomic Scale—The Adh Experience [PDF]
, 2000 Uwe Ohler
openalex +1 more source
Genomics‐led approach to drug testing in models of undifferentiated pleomorphic sarcoma
Molecular Oncology, EarlyView.GA text Genomic data from undifferentiated pleomorphic sarcoma patients and preclinical models were used to inform a targeted drug screen. Selected compounds were tested in 2D and 3D cultures of UPS cell lines. A combination of trametinib and infigratinib was synergistic in the majority of UPS cell lines tested, which was further confirmed in an ex ...
Piotr J. Manasterski +19 more
wiley +1 more source
A study of Genomic Prediction across Generations of Two Korean Pig Populations
Animals, 2019 Genomic models that incorporate dense marker information have been widely used for predicting genomic breeding values since they were first introduced, and it is known that the relationship between individuals in the reference population and selection ...
Beatriz Castro Dias Cuyabano +3 more
doaj +1 more source
Prediction of the Archaeal Exosome and Its Connections with the Proteasome and the Translation and Transcription Machineries by a Comparative-Genomic Approach [PDF]
, 2001 Eugene V. Koonin +2 more
openalex +1 more source
Genomic biomarkers in prostate cancer. [PDF]
, 2018 Prostate cancer is the most common non-cutaneous cancer among men in the United States. In the last decade there has been a rapid expansion in the field of biomarker assays for diagnosis, prognosis, and treatment prediction in prostate cancer.
Cooperberg, Matthew R +3 more
core
Unraveling LINE‐1 retrotransposition in head and neck squamous cell carcinoma
Molecular Oncology, EarlyView.The novel RetroTest method allows the detection of L1 activation in clinical samples with low DNA input, providing global L1 activity and the identification of the L1 source element. We applied RetroTest to a real‐world cohort of HNSCC patients where we reported an early L1 activation, with more than 60% of T1 patients showing L1 activity.
Jenifer Brea‐Iglesias +12 more
wiley +1 more source
Genomic selection on cacao for disease resistance : S04T08 [PDF]
, 2013 Under favorable conditions, diseases can cause losses up to 100% in cacao. Breeding has been the most effective strategy in reducing these losses. However, breeding is limited by the: a) long generation time; b) large tree size (9 m2/tree); c) multiple ...
Clément, Didier +6 more
core
Molecular Oncology, EarlyView.Overexpression of CHRDL2 in colon cancer cells makes them more stem‐like and resistant to chemo‐ and radiotherapy. CHRDL2‐high cells have upregulation of the WNT pathway, genes involved in the DNA damage response (DDR) pathway and epithelial‐to‐mesenchymal transition (EMT). This leads to quicker repair of damaged DNA and more cell migration.
Eloise Clarkson, Annabelle Lewis
wiley +1 more source
Molecular Oncology, EarlyView.Analysis of treatment‐naïve high‐grade serous ovarian carcinoma (HGSOC) and control tissues for ERVs, LINE‐1 (L1), inflammation, and immune checkpoints identified five clusters with diverse patient recurrence‐free survivals. An inflammation score was calculated and correlated with retroelement expression, where one novel cluster (Triple‐I) with high ...
Laura Glossner +6 more
wiley +1 more source
Molecular Oncology, EarlyView.In luminal (ER+) breast carcinoma (BC), miRNA profiling identified miR‐195‐5p as a key regulator of proliferation that targets CHEK1, CDC25A, and CCNE1. High CHEK1 expression correlates with worse relapse‐free survival after chemotherapy, especially in patients with luminal A subtype.
Veronika Boušková +14 more
wiley +1 more source